Probucol alleviates atherosclerosis and improves high density lipoprotein function

Background: Probucol is a unique hypolipidemic agent that decreases high density lipoprotein Cholesterol (HDL-C). However, it is not definite that whether probucol hinders the progression of atherosclerosis by improving HDL function.

Methods: Eighteen New Zealand White rabbits were randomly divided into the control, atherosclerosis and probucol groups. Control group were fed a regular diet; the atherosclerosis group received a high fat diet, and the probucol group received the high fat diet plus probucol. Hepatocytes and peritoneal macrophages were isolated for [(3)H] labeled Cholesterol efflux rates and expression of ABCA1 and SR-B1 at gene and protein levels; venous blood was collected for serum paraoxonase 1, myeloperoxidase activity and lipid analysis. Aorta were prepared for morphologic and immunohistochemical analysis after 12 weeks.

Results: Compared to the atherosclerosis group, the paraoxonase 1 activity, Cholesterol efflux rates, expression of ABCA1 and SR-BI in hepatocytes and peritoneal macrophages, and the level of ABCA1 and SR-BI in aortic lesions were remarkably improved in the probucol group, But the serum HDL Cholesterol concentration, myeloperoxidase activity, the IMT and the percentage plaque area of aorta were significantly decreased.

Conclusion: Probucol alleviated atherosclerosis by improving HDL function. The mechanisms include accelerating the process of reverse Cholesterol transport, improving the anti-inflammatory and anti-oxidant functions.